Elevance Health posted $418 million in profit for the fourth quarter of 2024, a figure that surpassed Wall Street's expectations despite decreasing 51% year-over-year. | Elevance Health posted $418 million in profit for the fourth quarter of 2024,

(Reuters) -Elevance Health on Thursday posted quarterly profit slightly above Wall Street expectations, helped by lower-than-expected spending on medical care for its members. The results lifted Elevance's shares more than 5% before the bell and also boosted peers such as Cigna and CVS Health.

Financial writer recommends buying Elevance Health stock despite recent drop, citing strong industry trends and potential for significant upside.

U.S. stocks are drifting near a record as Wall Street’s recent rally loses some momentum. The S&P 500 slipped 0.1% in early trading Thursday, a day after after pulling to the edge of its all-time high set in early December.

Elevance Health delivered earnings and 2025 guidance that broadly met analysts’ expectations, likely providing some relief to investors after a difficult third quarter. The fourth-quarter results mark

Premium revenue is expected to rise in the low double-digit percentage range, while product revenue rises in the low single-digit range and service fees come in flat year-over-year. Overall, operating revenue should climb in the high-single to low-double-digit range.

Elevance Health Inc. (ELV), while reporting weak fourth-quarter earnings below market estimates, on Thursday issued fiscal 2025

Elevance Health (ELV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Scott Fidel from

For the year, the company reported profit of $5.98 billion, or $25.68 per share. Revenue was reported as $175.2 billion. Elevance Health expects full-year earnings in the range of $34.15 to $34.85 per share.

Delving into the details, we found 50% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $248,785, and 4 were calls, valued at $134,250.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Elevance Health (ELV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Mark Kaye, the chief financial officer, said the company took a "very disciplined approach between competitiveness and underwriting."